Key ASCO Presentations Issue 7, 2010 First-Line Erlotinib with or without Chemotherapy for Never or Light Smokers with Advanced Non-Small Cell Lung Cancer (NSCLC) For more visit ResearchToPractice.com/5MJCMT2010
CME INFORMATION OVERVIEW OF ACTIVITY Each year, thousands of clinicians and basic scientists sojourn to the American Society of Clinical Oncology (ASCO) Annual Meeting to learn about recent clinical advances that yield alterations in state-of-the-art management for all tumor types. Attracting tens of thousands of attendees from every corner of the globe to both unveil and digest the latest research, ASCO is unmatched in attendance and clinical relevance. Results presented from ongoing trials lead to the emergence of new therapeutic agents and changes in the indications for existing treatments across all cancer medicine. Despite the importance of the conference, the demands of routine practice often limit the amount of time oncology clinicians can realistically dedicate to travel and learning. To bridge the gap between research and patient care, this CME activity will deliver a serial review of the key presentations from the ASCO Annual Meeting and expert perspectives on how these new evidence-based concepts can be applied to routine clinical care. This activity will assist medical oncologists and other cancer clinicians in the formulation of optimal clinical management strategies for patients with diverse forms of cancer. LEARNING OBJECTIVE Compare and contrast the value of EGFR mutation status versus former smoking status in the accurate identification of patients likely to benefit from first-line EGFR tyrosine kinase inhibitor therapy, with or without concurrent chemotherapy. ACCREDITATION STATEMENT Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. CREDIT DESIGNATION STATEMENT Research To Practice designates this educational activity for a maximum of 0.25 AMA PRA Category 1 Credits. Physicians should only claim credit commensurate with the extent of their participation in the activity. HOW TO USE THIS CME ACTIVITY This CME activity contains slides. To receive credit, the participant should review the slide presentation and complete the Educational Assessment and Credit Form located at CME.ResearchToPractice.com. CONTENT VALIDATION AND DISCLOSURES Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. FACULTY The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Roy S Herbst, MD, PhD Professor of Medicine; Chief, Section of Thoracic Medical Oncology, Department of Thoracic/Head and Neck Medical Oncology; Barnhart Family Distinguished Professor in Targeted Therapies, The University of Texas MD Anderson Cancer Center Houston, Texas Advisory Committee: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Lilly USA LLC; Consulting Agreements: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech BioOncology, Lilly USA LLC, SynDevRx Inc; Paid Research: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech BioOncology, Geron, Novartis Pharmaceuticals Corporation, Oncothyreon, OSI Oncology, Sanofi-Aventis. Corey J Langer, MD Professor of Medicine, University of Pennsylvania; Vice Chair Radiation Therapy Oncology Group Philadelphia, Pennsylvania Advisory Committee: Abbott Laboratories, Abraxis BioScience, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix, Bristol-Myers Squibb Company, Caris Diagnostics Inc, Clarient Inc, Genentech BioOncology, ImClone Systems Incorporated, Lilly USA LLC, Morphotek Inc, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc, Pfizer Inc, Sanofi-Aventis; Paid Research: Bristol-Myers Squibb Company, Genentech BioOncology, ImClone Systems Incorporated, Lilly USA LLC, OSI Oncology, Pfizer Inc; Speakers Bureau: Bristol-Myers Squibb Company, Genentech BioOncology, ImClone Systems Incorporated, Lilly USA LLC, OSI Oncology. Mark A Socinski, MD Professor of Medicine, Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center University of North Carolina Chapel Hill, North Carolina Data and Safety Monitoring Board: Bayer HealthCare Pharmaceuticals; Paid Research: Abraxis BioScience, Celgene Corporation, Genentech BioOncology, GlaxoSmithKline, Lilly USA LLC, Pfizer Inc; Speakers Bureau: Genentech BioOncology, GlaxoSmithKline, Lilly USA LLC, Sanofi-Aventis. EDITOR Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abraxis BioScience, Allos Therapeutics, Amgen Inc, AstraZeneca Pharmaceuticals LP, Aureon Laboratories Inc, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, Genzyme Corporation, Lilly USA LLC, Millennium Pharmaceuticals Inc, Monogram BioSciences Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Sanofi- Aventis and Spectrum Pharmaceuticals Inc. RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose. This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors. This program is supported by educational grants from Bristol- Myers Squibb Company, Celgene Corporation, Genentech BioOncology and Millennium Pharmaceuticals Inc. Last review date: July 2010 Expiration date: July 2011
Key ASCO Presentations Issue 7, 2010 To go directly to the slides and commentary, click here. Last Friday we hosted our annual daylong lung cancer Think Tank with seven renowned investigators, co-chaired by Tom Lynch (be on the lookout for the highlights audio program). One of the main objectives of this closed recording session was to review data sets from Chicago, and this dizzying scientific chat included discussion of the following work profiled in the enclosed slide sets: 1. Crizotinib in patients with EML4-ALK mutations An update of the stunning Phase I-II data first presented at ASCO 09 included impressive waterfall plots in which almost all patients had reduced tumor sizes with this not-yet available agent. Approximately four to five percent of patients harbor this newly described translocation that fits the classic oncogene addiction model, and at the Think Tank Dr Lynch described one such individual from his practice who entered this study with substantial symptomatic tumor burden and is still in response two years later. All in attendance agreed on the urgency of making this agent available and of standardizing and disseminating the assay technology, but the faculty was unsure how long this will actually take. 2. EGFR TKIs versus chemotherapy for patients with EGFR mutations A CALGB trial in first-line metastatic disease reinforced recent study results clearly demonstrating that a TKI without chemo is preferred for these patients. In contrast, the confusing and incomplete BR19 trial suggested the possibility that in the adjuvant setting, not only would EGFR TKIs not be beneficial, but for very much unknown reasons they could also be detrimental. Specifically because of this and one prior Stage III data set, there was a strong sentiment among the Think Tank investigators not to use these agents as adjuvant therapy outside a protocol setting. By the end of this amazing day, it was apparent that a new tissue-based algorithm for systemic treatment of advanced non-small cell lung cancer was on the table. Specifically, the faculty endorsed the baseline evaluation for patients with adequate tumor specimens for EGFR and EML4-ALK mutations and maybe K-ras, which might be predictive of benefit with sorafenib. For patients with needle biopsies without the necessary tumor quantity to conduct these assays, the decision regarding rebiopsy must be individualized based on smoking history, site of disease and performance status. Ed Kim, who first reported his landmark BATTLE trial at AACR followed by
more data from Roy Herbst at ASCO cautioned that core biopsies by interventional radiology are much more likely to yield adequate tissue than those obtained by bronchoscopy. After hearing MD Anderson coinvestigator John Heymach comment on the unprecedented translational data in BATTLE, it was clear this was the future paradigm of lung cancer research. 3. Palliative (supportive) care extends survival in the advanced disease setting In what some view as the biggest surprise of ASCO, a Harvard randomized trial demonstrated marked OS increases for patients who visited a palliative care specialist about once a month. Dr Lynch had a number of patients in this study and believes the benefits were primarily the result of better management of depression, anxiety and existential angst. All agreed that If this was a drug, we d use it. How to get this advance to patients is unclear. 4. Older patients may benefit from doublet chemotherapy in first-line advanced disease This plenary presentation confirmed an emerging theme within oncology: Older patients who can safely tolerate standard therapy derive the same benefits as younger patients. Next up on our final ASCO issue of 5-Minute Journal Club: GI cancers and a provocative study in pancreatic cancer. Neil Love, MD Research To Practice Miami, Florida Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Research To Practice designates each of the five educational activities, comprised of a slide set, for a maximum of 0.25 AMA PRA Category 1 Credits TM. Physicians should only claim credit commensurate with the extent of their participation in the activity. This program is supported by educational grants from Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology and Millennium Pharmaceuticals Inc. Research To Practice One Biscayne Tower 2 South Biscayne Boulevard, Suite 3600 Miami, FL 33131 This email was sent to you by Dr Neil Love and Research To Practice. To unsubscribe to future email requests and announcements, click here. To unsubscribe from all email communications, including CME/CNE activities sent by Research To Practice, click here. To update your information on our current distribution lists, click here.
First-Line Erlotinib with or without Chemotherapy for Never or Light Smokers with Advanced Non-Small Cell Lung Cancer (NSCLC) Presentation discussed in this issue Jänne PA et al. Randomized phase II trial of erlotinib (E) alone or in combination with carboplatin/paclitaxel (CP) in never or light former smokers with advanced lung adenocarcinoma: CALGB 30406. Proc ASCO 2010;Abstract 7503. Slides from a presentation at ASCO 2010 and transcribed comments from recent interviews with Roy S Herbst, MD, PhD (6/23/10), Corey J Langer, MD (7/2/10) and Mark A Socinski, MD (6/4/10) For more visit ResearchToPractice.com/5MJCMT2010
For more visit ResearchToPractice.com/5MJCMT2010
For more visit ResearchToPractice.com/5MJCMT2010
For more visit ResearchToPractice.com/5MJCMT2010
For more visit ResearchToPractice.com/5MJCMT2010
For more visit ResearchToPractice.com/5MJCMT2010